Sputnik V: research, production, vaccination campaign and export
Sputnik V: research, production, vaccination campaign and export

Author(s): Iwona Wiśniewska, Jadwiga Rogoża
Subject(s): Government/Political systems, Security and defense, Health and medicine and law
Published by: OSW Ośrodek Studiów Wschodnich im. Marka Karpia
Keywords: Sputnik V; vaccine; COVID-19; Russian vaccines; mass vaccination campaign; COVID passports;
Summary/Abstract: In December 2020, Russia launched a mass-scale action for vaccinating its citizens with the domestically produced Sputnik V coronavirus vaccine. It was only on 2 February 2021 that the Gamaleya Institute, which developed the vaccine, announced the results of its phase-III clinical trials which showed that the vaccine’s efficacy rate was more than 91%. The way the Russian leadership reports on Sputnik V’s production and rollout is chaotic and the published data is incompatible and non-transparent. Only rough information has been shared regarding the number of vaccinations performed thus far: the Ministry of Health has failed to provide precise figures and, according to estimates by the Gamaleya Institute, the immunisation campaign has so far covered 1.5–2 million citizens. However, these figures are inconsistent with the data reported by the individual regions.

• Details
• Contents